問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans Center Hospital Yuli Branch (在職)

Division of Psychiatry

Yuli Hospital Ministry of Health and Welfare (在職)

Division of Psychiatry

Tri-Service General Hospital (在職)

Division of Others-

MacKay Memorial Hospital (在職)

Division of Obstetrics & Gynecology

更新時間：2023-09-19

陳震宇
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳震宇

Taipei Veterans Center Hospital Yuli Branch

Division of Psychiatry

List

9Cases

2006-05-01 - 2009-12-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-12-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-03-01 - 2009-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-04-01 - 2010-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2010-10-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2010-01-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-11-01 - 2010-10-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB